Cajamarca-Baron Jairo, Guavita-Navarro Diana, Buitrago-Bohorquez Jhon, Gallego-Cardona Laura, Navas Angela, Cubides Hector, Arredondo Ana María, Escobar Alejandro, Rojas-Villarraga Adriana
Fundación Universitaria de Ciencias de la Salud (FUCS), Hospital San José, Bogotá, Colombia.
Servicio de Neurología, Fundación Universitaria de Ciencias de la Salud (FUCS), Hospital San José, Bogotá, Colombia.
Reumatol Clin. 2021 Aug-Sep;17(7):408-419. doi: 10.1016/j.reuma.2020.08.004. Epub 2020 Sep 11.
It is not clear whether patients with some degree of immunosuppression have worse outcomes in SARS-CoV-2 infection, compared to healthy people.
To carry out a narrative review of the information available on infection by SARS-CoV-2 in immunosuppressed patients, especially patients with cancer, transplanted, neurological diseases, primary and secondary immunodeficiencies.
Patients with cancer and recent cancer treatment (chemotherapy or surgery) and SARS-CoV-2 infection have a higher risk of worse outcomes. In transplant patients (renal, cardiac and hepatic), with neurological pathologies (multiple sclerosis [MS], neuromyelitis optica [NMODS], myasthenia gravis [MG]), primary immunodeficiencies and infection with human immunodeficiency virus (HIV) in association with immunosuppressants, studies have shown no tendency for worse outcomes.
Given the little evidence we have so far, the behaviour of SARS-CoV-2 infection in immunosuppressed patients is unclear, but current studies have not shown worse outcomes, except for patients with cancer.
与健康人相比，某种程度免疫抑制的患者感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）后预后是否更差尚不清楚。
对免疫抑制患者，尤其是癌症患者、移植患者、神经系统疾病患者、原发性和继发性免疫缺陷患者感染SARS-CoV-2的现有信息进行叙述性综述。
癌症患者以及近期接受过癌症治疗（化疗或手术）且感染SARS-CoV-2的患者预后较差的风险更高。在移植患者（肾移植、心脏移植和肝移植）、患有神经病理学疾病（多发性硬化症[MS]、视神经脊髓炎[NMODS]、重症肌无力[MG]）、原发性免疫缺陷以及感染人类免疫缺陷病毒（HIV）并使用免疫抑制剂的患者中，研究未显示出预后更差的倾向。
鉴于我们目前掌握的证据有限，SARS-CoV-2在免疫抑制患者中的表现尚不清楚，但目前的研究未显示出除癌症患者外预后更差的情况。
